Malignant Pleural Effusion Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Genelux Corporation, RS Oncology, Canderl Therapeutics, Abnoba Korea, Jiangsu

Posted on
by

Malignant Pleural Effusion Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Genelux Corporation, RS Oncology, Canderl Therapeutics, Abnoba Korea, Jiangsu
The Key Malignant Pleural Effusion Companies in the market include – Genelux Corporation, RS Oncology, Canderl Therapeutics, Abnoba Korea, Jiangsu Simcere Pharmaceutical, Novartis, and others.

DelveInsight’s “Malignant Pleural Effusion Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Malignant Pleural Effusion, historical and forecasted epidemiology as well as the Malignant Pleural Effusion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Malignant Pleural Effusion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Malignant Pleural Effusion Market Forecast

 

Some of the key facts of the Malignant Pleural Effusion Market Report:

  • The Malignant Pleural Effusion market size across the 7MM is forecasted to rise from USD 2,423 million in 2025 to USD 3,736 million by 2034, reflecting a CAGR of 4.90%.

  • In June 2024, RS Oncology, a private biopharmaceutical company dedicated to developing innovative treatments for rare and aggressive cancers, shared positive findings from its Phase I study on patients with Malignant Pleural Mesothelioma (MPM) and Malignant Pleural Effusion (Malignant Pleural Effusion), or Malignant Pleural Effusion linked to other solid tumors, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

  • The United States accounts for the largest share of incident Malignant Pleural Effusion cases within the 7MM, representing roughly 38%.

  • Within the 7MM, the United States recorded the highest number of incident pleural effusion cases, representing approximately 40% of the total cases in 2023.

  • In the United States, about 75% of all incident malignant pleural effusion cases were diagnosed, while the remaining cases went undiagnosed.

  • Germany holds the largest share of diagnosed malignant pleural effusion cases among the EU4 and the UK, representing approximately 25% of total diagnosed cases in the region.

  • By tumor type, within the 7MM, malignant pleural effusion was most frequently associated with lung cancer, accounting for around 30% of diagnosed cases, followed by breast cancer.

  • Key Malignant Pleural Effusion Companies: Genelux Corporation, RS Oncology, Canderl Therapeutics, Abnoba Korea, Jiangsu Simcere Pharmaceutical, Novartis, and others

  • Key Malignant Pleural Effusion Therapies: GL-ONC1-003, RSO-021, CAN-2409, Abnoba Viscum F 20mg, Endostar, zoledronic acid, and others

  • The Malignant Pleural Effusion market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Malignant Pleural Effusion pipeline products will significantly revolutionize the Malignant Pleural Effusion market dynamics.

 

Malignant Pleural Effusion Overview

A well-known side effect of both thoracic and extra thoracic cancers is malignant pleural effusion. However, recent developments in the treatment of malignant pleural effusions have changed the disease’s morbidity.

 

Get a Free sample for the Malignant Pleural Effusion Market Report

https://www.delveinsight.com/report-store/malignant-pleural-effusion-market

 

Malignant Pleural Effusion Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Malignant Pleural Effusion Epidemiology Segmentation:

The Malignant Pleural Effusion market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Incident Cases of Pleural Effusion in the 7MM

  • Total Incident Cases of Malignant Pleural Effusion in the 7MM

  • Total Diagnosed Cases of Malignant Pleural Effusion in the 7MM

  • Total Incident Cases of Malignant Pleural Effusion by Tumor Type in the 7MM

  • Total Treated Cases of Malignant Pleural Effusion in the 7MM

 

Download the report to understand which factors are driving Malignant Pleural Effusion epidemiology trends @ Malignant Pleural Effusion Epidemiology Forecast

 

Malignant Pleural Effusion Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Malignant Pleural Effusion market or expected to get launched during the study period. The analysis covers Malignant Pleural Effusion market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Malignant Pleural Effusion Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Malignant Pleural Effusion Therapies and Key Companies

  • GL-ONC1-003: Genelux Corporation

  • RSO-021: RS Oncology

  • CAN-2409: Canderl Therapeutics

  • Abnoba Viscum F 20mg: Abnoba Korea

  • Endostar: Jiangsu Simcere Pharmaceutical

  • zoledronic acid: Novartis

 

Discover more about therapies set to grab major Malignant Pleural Effusion market share @ Malignant Pleural Effusion Treatment Market

 

Malignant Pleural Effusion Market Strengths

  • Improved imaging technologies (CT scans, ultrasounds) and diagnostic procedures (thoracentesis, pleural biopsy) enhance early and accurate detection of Malignant Pleural Effusion.

  • The development of procedures like pleurodesis and indwelling pleural catheters provide effective symptomatic relief and improve quality of life for patients.

 

Malignant Pleural Effusion Market Opportunities

  • Advances in genetic and molecular profiling can enable more personalized treatment approaches, improving outcomes and reducing side effects.

  • Emerging treatments, such as oncolytic virus therapy and localized drug delivery systems, hold promise for more effective management of MPE.

 

Scope of the Malignant Pleural Effusion Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Malignant Pleural Effusion Companies: Genelux Corporation, RS Oncology, Canderl Therapeutics, Abnoba Korea, Jiangsu Simcere Pharmaceutical, Novartis, and others

  • Key Malignant Pleural Effusion Therapies: GL-ONC1-003, RSO-021, CAN-2409, Abnoba Viscum F 20mg, Endostar, zoledronic acid, and others

  • Malignant Pleural Effusion Therapeutic Assessment: Malignant Pleural Effusion current marketed and Malignant Pleural Effusion emerging therapies

  • Malignant Pleural Effusion Market Dynamics: Malignant Pleural Effusion market drivers and Malignant Pleural Effusion market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Malignant Pleural Effusion Unmet Needs, KOL’s views, Analyst’s views, Malignant Pleural Effusion Market Access and Reimbursement

 

To know more about Malignant Pleural Effusion companies working in the treatment market, visit @ Malignant Pleural Effusion Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Malignant Pleural Effusion Market Report Introduction

2. Executive Summary for Malignant Pleural Effusion

3. SWOT analysis of Malignant Pleural Effusion

4. Malignant Pleural Effusion Patient Share (%) Overview at a Glance

5. Malignant Pleural Effusion Market Overview at a Glance

6. Malignant Pleural Effusion Disease Background and Overview

7. Malignant Pleural Effusion Epidemiology and Patient Population

8. Country-Specific Patient Population of Malignant Pleural Effusion

9. Malignant Pleural Effusion Current Treatment and Medical Practices

10. Malignant Pleural Effusion Unmet Needs

11. Malignant Pleural Effusion Emerging Therapies

12. Malignant Pleural Effusion Market Outlook

13. Country-Wise Malignant Pleural Effusion Market Analysis (2020–2034)

14. Malignant Pleural Effusion Market Access and Reimbursement of Therapies

15. Malignant Pleural Effusion Market Drivers

16. Malignant Pleural Effusion Market Barriers

17. Malignant Pleural Effusion Appendix

18. Malignant Pleural Effusion Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/